Los Altos, CA, United States
Los Altos, CA, United States
SEARCH FILTERS
Time filter
Source Type

Dublin, Aug. 15, 2017 (GLOBE NEWSWIRE) -- The "Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030" report has been added to Research and Markets' offering. The Non-Invasive Cancer Diagnostics Market (2nd Edition), 2017-2030' report provides an extensive study on liquid biopsy kits/assays that are either commercialized or are under development for diagnosis and/or monitoring of different types of cancer. The market is characterized by the presence of several companies that have proprietary technologies/platforms for either isolation/enrichment/enumeration of CTCs or for molecular characterization/sequencing of the genetic material extracted from the CTCs/exosomes. Based on these platforms, a number of liquid biopsy kits and systems are being developed for non-invasive diagnosis, prognosis, and patient and recurrence monitoring of different cancer indications. Such kits are likely to transform the cancer diagnostics market with many commercial success stories in the near future. The market is primarily led by start-ups/small companies, such as (in alphabetical order) CellMax Life, Celsee Diagnostics, Datar Genetics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences, iCellate Medical, Inivata, IVDiagnostics, LCM Genect and MDNA Life Sciences. It also has presence of mid to large-sized pharma players; notable examples include (in alphabetical order) Biocartis, Counsyl, Foundation Medicine, Genomic Health and NeoGenomics Laboratories. In addition to the aforementioned players, a number of pharma giants are also developing assets in this field. Prominent players under this category include (in alphabetical order) Affymetrix, Menarini Silicon Biosystems, Myriad Genetics, QIAGEN, Roche, Siemens Healthineers and Thermo Fisher Scientific. As companies continue to initiate and expand their research programs and platforms in this area, one of the key objectives of this report was to understand the future potential of the market. In addition, we have provided a comprehensive market estimation to determine the global evolution of the liquid biopsy market. This has been done by evaluating the likely success of key applications of early diagnosis, recurrence monitoring and patient monitoring. We have included insights on the likely regional evolution of the market covering US, EU5 and rest of the world. In addition, we have estimated the likely contribution of different target patient populations to the global market; this covered key indications including (in alphabetical order) bladder cancer, breast cancer, colorectal cancer, gastric cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer and prostate cancer. Further, we segmented the market by the type of markers (CTCs, ctNAs, exosomes) and the sample source (blood, urine, saliva) used in different liquid biopsies. In order to account for uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios for the time period 2017-2030. The conservative, base and optimistic scenarios represent three different tracks of the industry's evolution. The research, analysis and insights presented in this report are backed by the deep understanding of key insights gathered from both secondary and primary research. 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Cancer Statistics and Burden of the Disease 3.3. Importance of Early Detection in Cancer 3.4. Detecting Cancer: Screening vs. Diagnosis 3.5. Conventional Invasive Cancer Diagnostic Tests 3.5.1. Biopsy 3.5.1.1. Fine Needle Aspiration Biopsy 3.5.1.2. Core Needle Biopsy 3.5.1.3. Vacuum-Assisted Biopsy 3.5.1.4. Image-Guided Biopsy 3.5.1.5. Sentinel Node Biopsy 3.5.1.6. Surgical Biopsy 3.5.1.7. Endoscopic Biopsy 3.5.1.8. Bone Marrow Biopsy 3.5.2. Endoscopy 3.6. Need for Non-Invasive Approaches 3.7. Costs and Benefits Associated with Non-Invasive Tests 4. CONCEPT OF NON-INVASIVE CANCER SCREENING AND DIAGNOSTICS 4.1. Chapter Overview 4.2. Diagnostic Imaging 4.2.1. Magnetic Resonance Imaging (MRI) 4.2.2. Mammography 4.2.3. Bone Scan 4.2.4. Computerized Tomography (CT) Scan 4.2.5. Integrated PET-CT Scan 4.2.6. Ultrasound 4.2.7. Barium Enema 4.3. Screening Assays 4.3.1. Papanicolaou Test (Pap Test) and Human Papilloma Virus Test (HPV Test) 4.3.2. Tumor Marker Test 4.3.3. Fecal Occult Blood Tests (FOBT) 4.3.4. Digital Rectal Exam (DRE) 4.3.5. Multigated Acquisition (MUGA) Scan 4.4. Advanced Non-Invasive Approaches 4.4.1. Liquid Biopsy 4.4.2. Cytogenetic/Gene Expression Studies 4.4.3. Molecular Signature Based Non-Invasive Methods 4.4.4. Saliva-Based Oral Cancer Diagnostics 4.4.5. Vital Staining 4.4.6. Optical Biopsy 4.4.7. Other Techniques 5. MARKET LANDSCAPE 5.1. Chapter Overview 5.2. Liquid Biopsy: Development Landscape 5.2.1. Liquid Biopsy Tests: Distribution by Development Stage 5.2.2. Liquid Biopsy Tests: Distribution by Sample Type 5.2.3. Liquid Biopsy Tests: Distribution by Type of Markers Detected 5.2.4. Liquid Biopsy Tests: Distribution by Indication 5.2.5. Liquid Biopsy Tests: Distribution by Type of Application 5.2.6. Liquid Biopsy Tests: Distribution by Geographical Coverage 5.2.7. Liquid Biopsy Tests: Distribution by Leading Players 5.3. Liquid Biopsy: Technologies, Platforms, Systems and Instruments 6. LIQUID BIOPSY MARKET: KEY INSIGHTS 6.1. Chapter Overview 6.2. Liquid Biopsy Tests: Competitive Landscape of Developers 6.3. Liquid Biopsy Tests: Distribution by Application and Target Indications 6.4. Emerging Trends on Non-Invasive Cancer Diagnostics on Social Media 6.4.1. Non-Invasive Cancer Diagnostics: Historical Trends by Twitter Volume (2010-2016) 6.4.2. Non-Invasive Cancer Diagnostics: Twitter Word Cloud (2010, 2012, 2014, 2016) 6.4.3. Non-Invasive Cancer Diagnostics: Twitter Trends for Popular Indications (2010-2016) 6.4.4. Non-Invasive Cancer Diagnostics: Twitter Trends for Samples Types (2010-2016) 7. LIQUID BIOPSY: DETAILED OUTLOOK 7.1. Chapter Overview 7.2. Non-Invasive Methods Over Biopsies for Detection of Cancer 7.3. Circulating Biomarkers for Cancer 7.3.1. Circulating Tumor Cells (CTCs) 7.3.1.1. Advantages Associated with the Use of CTCs 7.3.1.2. Challenges Associated with the Use of CTCs 7.3.2. Circulating Tumor DNA (ctDNA) 7.3.3. Exosomes 7.4. Liquid Biopsy Based Tests and Systems 7.4.1. BioFluidica CTC Isolation Technology, CTC Analysis System and Test, BioFluidica/Roche 7.4.2. CancerIntercept Detect and CancerIntercept Monitor, Pathway Genomics 7.4.3. Cancertrack, Datar Genetics 7.4.4. CellMax-LBx Liquid Biopsy and CellMax-CRC Colorectal Cancer Blood Test, CellMax Life 7.4.5. CELLSEARCH System and CELLSEARCH CTC Test, Menarini Silicon Biosystems 7.4.6. cobas EGFR Mutation Test v2, Roche 7.4.7. LiquidBiopsy Rare Cell Isolation Platform, ClearID Total Insight Breast Cancer, ClearID Lung Cancer and Clear ID Melanoma, Cynvenio Biosystems 7.4.8. Oncocount, Oncotrace, Oncotrial and Metastat, R.G.C.C. Group 7.4.9. OncoBEAM CRC RAS Kit, Sysmex Inostics/Merck 7.4.10. OnTarget Assay, Boreal Genomics 7.4.11. PrediSeq-Prostate and PrediSeq-Lung, Predicine 7.4.12. SelectMDx, MDxHealth 7.4.13. ViewRNA CTC Platform and Assay, Affymetrix 7.4.14. Velox, IVDiagnostics 7.4.15. ApoStream System and Technology, ApoCell 7.4.16. IsoPic, iCellate Medical 7.4.17. Parsortix System, ANGLE 7.5. Companion Liquid Biopsies: Recent Developments 7.5.1. Biocept and Baylor College of Medicine 7.5.2. Tokai Pharmaceuticals and QIAGEN 7.5.3. ANGLE and MD Anderson Cancer Center 7.5.4. AstraZeneca and QIAGEN 7.5.5. Sysmex Inostics and Bayer Healthcare 8. VENTURE CAPITAL FUNDING 8.1. Chapter Overview 8.2. Types of Funding 8.3. Liquid Biopsy Market: Funding Instances, 2011-2017 8.4. Liquid Biopsy Market: Distribution by Year 8.5. Liquid Biopsy Market: Distribution of Type of Model 8.6. Leading Players: Distribution by Funding Instances 9. COMPANY VALUATION ANALYSIS 9.1. Chapter Overview 9.2. Company Valuation: Methodology 9.3. Company Valuation: Categorization by Multiple Parameters 9.3.1. Categorization by Google Hits Score 9.3.2. Categorization by Awards Score 9.3.3. Categorization by Twitter Score 9.3.4. Categorization by Twitter Followers Score 9.3.5. Categorization by Number of Products 9.3.6. Categorization by Uniqueness Score 9.3.7. Categorization by Weighted Average Score 10. LIQUID BIOPSY: KEY PLAYERS 10.1. Chapter Overview 10.2. Biocartis 10.2.1. Company Overview 10.2.2. Financial Performance 10.2.3. Product Portfolio 10.2.3.1. Idylla ctBRAF Mutation Assay (RUO) 10.2.3.2. Idylla ctKRAS Mutation Assay 10.2.3.3. Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO) 10.3. Biocept 10.3.1. Company Overview 10.3.2. Financial Performance 10.3.3. Product Portfolio 10.3.3.1. Target Selector Breast Cancer Test 10.3.3.2. Target Selector Lung Cancer Test 10.3.3.3. Target Selector Immuno-Oncology PD-L1 Test 10.3.3.4. Target Selector Gastric Cancer Test 10.3.3.5. Target Selector Colorectal Cancer Test 10.3.3.6. Target Selector Prostate Cancer Test 10.3.3.7. Target Selector Melanoma Test 10.4. Biodesix 10.4.1. Company Overview 10.4.2. Financial Information 10.4.3. Product Portfolio 10.4.3.1. GeneStrat 10.4.3.2. VeriStrat 10.5. Exosome Diagnostics 10.5.1. Company Overview 10.5.2. Financial Information 10.5.3. Product Portfolio 10.5.3.1. ExoDx Prostate (IntelliScore) 10.5.3.2. ExoDx Lung (ALK) 10.5.3.3. ExoDx Lung (EGFR/T790M) 10.5.3.4. ExoDx Solid Tumor 10.6. Genomic Health 10.6.1. Company Overview 10.6.2. Financial Performance 10.6.3. Product Portfolio 10.6.3.1. Oncotype SEQ Liquid Select 10.7. Guardant Health 10.7.1. Company Overview 10.7.2. Financial Information 10.7.3. Product Portfolio 10.7.3.1. Guardant360 10.8. NeoGenomics Laboratories 10.8.1. Company Overview 10.8.2. Financial Performance 10.8.3. Product Portfolio 10.8.3.1. NeoLAB HEME 10.8.3.2. NeoLAB Solid Tumor Monitor (NeoLAB SOLID TUMOR) 10.8.3.3. NeoLAB Prostate 10.8.3.4. NeoLAB EGFR T790M Liquid Biopsy 10.9. Personal Genome Diagnostics (PGDx) 10.9.1. Company Overview 10.9.2. Financial Information 10.9.3. Product Portfolio 10.9.3.1. MetDETECT 10.9.3.2. PlasmaSELECT R 64 10.9.3.3. LungSELECT 10.10. QIAGEN 10.11. Transgenomic 10.12. Trovagene 11. OTHER NON-INVASIVE CANCER DIAGNOSTICS 11.1. Chapter Overview 11.2. Non-Blood Based Biomarker Detection Tests 11.3. DNA Methylation Detection Tests 11.4. Fecal Occult Blood Test (FOBT) AND Fecal Immunochemical Test (FIT) 11.5. MicroRNA (miRNA) Based Test 11.6. Pigmented Lesion Assay 11.7. Stool DNA (sDNA) Testing 11.8. Volatile Organic Compound (VOC) Detection Test 11.9. Other Non-Invasive Cancer Diagnostics: Market Landscape 11.10. Other Non-Invasive Cancer Diagnostics: Survey Analysis 11.10.1. Survey Analysis: Seniority Level of Respondents 11.10.2. Survey Analysis: Type of Product Portfolio 11.10.3. Survey Analysis: Types of Products/Services Offered 11.10.4. Survey Analysis: Type of Application 11.10.5. Survey Analysis: Availability of the Products 11.10.6. Survey Analysis: Likely Market Size 12. MARKET SIZING AND FORECAST 12.1. Chapter Overview 12.2. Forecast Assumptions and Methodology 12.3. Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030 12.3.1. Liquid Biopsy Market Forecast, 2017-2030 12.3.2. Other Non-Invasive Cancer Diagnostics Market Forecast, 2017-2030 13. CONCLUSION 13.1. Timely Disease Detection and Subsequent Monitoring are Critical Elements of Patient Care in the Field of Oncology 13.2. Introduction of Sophisticated Molecular Diagnostics has Facilitated Better Cancer Management 13.3. Liquid Biopsy has Emerged as a Reliable Alternative to the Invasive Methods of Diagnosis 13.4. The Versatile and Patient Friendly Nature of these Diagnostic Tools Cater to a Wide Range of Applications 13.5. The Interest is Gradually Rising with Participation of Several Start-ups Across Different Geographies 13.6. In Addition to Liquid Biopsy, Development of Other Non-Invasive Tests will Further Strengthen the Ongoing Innovation 13.7. Rising Venture Capital Support is Indicative of a Lucrative Future Potential 13.8. Primarily Led by Liquid Biopsy, The Non-Invasive Cancer Diagnostics Market has Emerged as a Multi-Billion Dollar Market 14. INTERVIEW TRANSCRIPTS 14.1. Chapter Overview 14.2. Burkhard Jansen, MD, Chief Medical Officer, DermTech 14.3. Frank Szczepanski, President and CEO, IVDiagnostics 14.4. Riccardo Razzini, Sales and Marketing Manager, LCM Genect 14.5. Nathalie Bernard, Marketing Director, OncoDNA 14.6. Abizar Lakdawalla, Founder, ProXeom 14.7. Mark Li, CEO, Resolution Bioscience 14.8. Christer Ericsson, Chief Scientific Officer, iCellate Medical 14.9. Philippe Nore, CEO and Co-founder, MiNDERA 14.10. Jake Micallef, Chief Scientific Officer, VolitionRx 15. APPENDIX 1: TABULATED DATA 16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS For more information about this report visit https://www.researchandmarkets.com/research/sdm2rg/noninvasive


Patent
Boreal Genomics | Date: 2016-10-04

Methods and apparatus providing for the isolation of an unknown mutation from a sample comprising wild type nucleic acids and mutated nucleic acids through the application of time-varying driving fields and periodically varying mobility-altering fields to the sample within in an affinity matrix.


Dublin, Sept. 15, 2017 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides" report has been added to Research and Markets' offering. The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity? They are all listed in Chapter 10. All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data. i. Liquid Biopsy Market - Strategic Situation Analysis ii. Guide for Executives, Marketing, Sales and Business Development Staff iii. Guide for Management Consultants and Investment Advisors 1. Introduction and Market Definition 1.1 What is Liquid Biopsy? 1.2 The Sequencing Revolution 1.3 Market Definition 1.3.1 Volumes 1.3.2 Prices 1.3.3 Revenue Market Size 1.4 Methodology 1.4.1 Authors 1.4.2 Sources 1.5 A Spending Perspective on Liquid Biopsy 1.5.1 An Historical Look at Clinical Testing 2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer 2.1.3 Genomic Instrumentation Supplier 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier 2.1.4 Pharmaceutical/Reagent Supplier 2.1.5 Independent Testing Lab 2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Lab 2.1.9 Audit Body 2.1.10 Certification Body 2.2 Using Biopsies 2.2.1 Cancer 2.2.2 Precancerous conditions 2.2.3 Inflammatory conditions 2.3 Biopsy Sites 2.4 The Situation Today - Biopsy Analysis 2.5 Evidence of Cancer - Liquid Biopsy Technology 2.5.1 The Big Picture on Liquid Biopsy Technology 2.5.2 The Role of CTCs 2.5.2.1 Types of CTCs 2.5.2.2 CellSearch Detection- Ultimate Sensitivity 2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead 2.5.2.4 Maintrac Detection - The Microscope 2.5.2.5 Other Methods 2.5.3 ctDNA - Going Mainstream? 2.5.4 Exosomes and Micro Vesicles - New Kid on Block 2.6 Cancer Treatment Protocol Under Siege 2.6.1 Issues and Limitations to Liquid Biopsy Adoption - Double Diagnostics 2.6.2 The Cancer Screening Market Opportunity 2.6.2.1 GRAIL - What Is It? 2.6.3 Cancer Management vs. Diagnosis 2.6.3.1 The Role of Risk Assessment 2.6.3.2 Managing Therapy 2.6.3.3 Monitoring Disease - What Is It? 2.6.4 Phases of Adoption - Looking Into The Future 2.6.5 The Promise of Liquid Biopsy 2.7 Structure of Industry Plays a Part 2.7.1 Hospital Testing Share 2.7.2 Economies of Scale 2.7.2.1 Hospital vs. Central Lab 2.7.3 Physician Office Lab's 2.7.4 Physician's and POCT 2.8 Profiles of Key Players 2.8.1 Qiagen 2.8.2 Agena Bioscience 2.8.3 Angle plc 2.8.4 ApoCell 2.8.5 Biocept 2.8.6 BioFluidica 2.8.7 Bio-Rad Laboratories 2.8.8 Boreal Genomics 2.8.10 Chronix Biomedical 2.8.11 Clearbridge BioMedics 2.8.12 Cynvenio 2.8.13 Cytolumina Technologies Corp 2.8.14 CytoTrack 2.8.15 Diagnologix LLC 2.8.16 Epic Sciences 2.8.17 Exosome Diagnostics 2.8.18 Exosome Sciences 2.8.19 Fluidigm Corp 2.8.20 Fluxion Biosciences 2.8.21 Genomic Health 2.8.39 GRAIL 2.8.22 Guardant Health 2.8.23 HansaBiomed 2.8.23 Horizon Discovery 2.8.24 iCellate 2.8.25 Illumina 2.8.26 Inivata 2.8.27 Janssen Diagnostics 2.8.28 Molecular MD 2.8.29 Myriad Genetics 2.8.30 Natera 2.8.31 New Oncology 2.8.32 Personal Genome Diagnostics 2.8.33 RainDance Technologies 2.8.34 Rarecells SAS 2.8.35 Silicon Biosystems 2.8.36 Sysmex Inostics 2.8.37 SRI International 2.8.38 Trovagene 2.8.39 Freenome 3. Market Trends 3.1 Factors Driving Growth 3.1.1 Non Invasive Game Changer 3.1.2 Lower Cost 3.1.3 Greater Accuracy. 3.1.4 Wide Range of Potential Uses 3.1.5 Aging Population 3.2 Factors Limiting Growth 3.2.1 Lower prices 3.2.2 Lack of Standards. 3.2.3 Protocol Resistance. 3.2.4 Initial Adoption Has No Cost Savings 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role. 3.4 Diagnostic Technology Development 3.4.1 Next Generation Sequencing Fuels a Revolution 3.4.2 Impact of NGS on pricing 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magneto resistance based assay 4. Liquid Biopsy Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section 4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy 4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy 4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study 4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen 4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test 4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options 4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab 4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance 4.10 Biocept Q1 Revenues Rise With Test Volume Growth 4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers 4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood 4.13 Cynvenio to present new clinical data 4.14 EKF, Angle Collaborate for Liquid Biopsy Development 4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer 4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen 4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics 4.18 Merck Serono and Sysmex Inostics Announce Testing Center 4.19 Agena Bioscience Launches Smaller Format MassArray 4.20 Personal Genome Diagnostics Aims for FDA Clearance 4.21 HTG Molecular Diagnostics Files for IPO of up to $60M 4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter 4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs 4.24 Inivata Raises $6.6M to Develop ctDNA Assays 4.25 Epic Sciences Raises $30M in Private Financing 4.26 New Release in Line of Liquid Biopsy CLIA Tests 4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test 4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field 4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test 4.29 DNA in blood can track cancer development, response in real time 4.30 Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing 4.31 Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay 4.32 Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System 4.33 MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States 4.34 GATC Biotech's Liquid Biopsy Testing Takes Cost Lead 4.35 Liquid Biotech USA, Inc. Announces Completion of Clinical Study 4.36 Liquid biopsies more effective in some cases than tissue biopsies 4.37 Cancer Genetics, Inc. and ApoCell Announce Partnership for Rare Cell Capture and Detection 4.38 Exosome Diagnostics Launches Liquid Biopsy Test to Rule Out High-Grade Prostate Cancer 4.39 Liquid Biopsy Tests Partially Validated 4.40 FDA Approves Liquid Biopsy 4.41 Liquid Biopsy Predicts Colon Cancer Recurrence 4.42 WaveSense Receives CE-IVD Mark for Cell Enrichment Platform 4.43 For Liquid Biopsy, Size Matters 4.44 Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz 4.45 Trovagene, USC Collaborate on Deployment of Urine-Based Liquid Biopsy Test 4.46 Circulogene liquid biopsy detects new tumor mass earlier than current imaging methods 4.47 Clinical Utility of Biocept's Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium 4.48 Trovagene to Focus More on Liquid Biopsy Testing Market 4.49 Pancreatic Cancer Gets Prognostic Tool from Liquid Biopsy 4.50 New Start-up to Work on Scalpel-free Liquid Biopsies 4.51 RareCyte announces $30M round 4.52 Liquid Biopsies May Never Replace Tissue Biopsies 4.53 Karius reels in $50M to ramp up infectious disease liquid biopsy 4.54 Liquid Biopsy Passes Test for Nasopharyngeal Cancer 4.55 Exosome Diagnostics Launches the MedOncAlyzer Pan-Cancer Panel 4.56 Lonza Acquires HansaBioMed, Invests in Exosomics 4.57 Controversial Test Highlights Precision Medicine Marketing, Regulatory Issues 4.58 Trovagene Announces Agreement with Global Biopharmaceutical Company 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Size For more information about this report visit https://www.researchandmarkets.com/research/88k95t/liquid_biopsy


News Article | September 28, 2017
Site: www.prnewswire.com

The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests. GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening. Use independent research that makes you the expert. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. Get an extra player on your team as unlimited assistance and breakout data is included with your purchase. Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers. What is the size of the huge screening opportunity? They are all listed in Chapter 10. All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data. i. Liquid Biopsy Market - Strategic Situation Analysis ii. Guide for Executives, Marketing, Sales and Business Development Staff iii. Guide for Management Consultants and Investment Advisors 1. Introduction and Market Definition 1.1 What is Liquid Biopsy? 1.2 The Sequencing Revolution 1.3 Market Definition 1.3.1 Volumes 1.3.2 Prices 1.3.3 Revenue Market Size 1.4 Methodology 1.4.1 Authors 1.4.2 Sources 1.5 A Spending Perspective on Liquid Biopsy 1.5.1 An Historical Look at Clinical Testing 2. Market Overview 2.1 Players in a Dynamic Market 2.1.1 Academic Research Lab 2.1.2 Diagnostic Test Developer 2.1.3 Genomic Instrumentation Supplier 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier 2.1.4 Pharmaceutical/Reagent Supplier 2.1.5 Independent Testing Lab 2.1.6 Public National/regional lab 2.1.7 Hospital lab 2.1.8 Physician Lab 2.1.9 Audit Body 2.1.10 Certification Body 2.2 Using Biopsies 2.2.1 Cancer 2.2.2 Precancerous conditions 2.2.3 Inflammatory conditions 2.3 Biopsy Sites 2.4 The Situation Today - Biopsy Analysis 2.5 Evidence of Cancer - Liquid Biopsy Technology 2.5.1 The Big Picture on Liquid Biopsy Technology 2.5.2 The Role of CTCs 2.5.2.1 Types of CTCs 2.5.2.2 CellSearch Detection- Ultimate Sensitivity 2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead 2.5.2.4 Maintrac Detection - The Microscope 2.5.2.5 Other Methods 2.5.3 ctDNA - Going Mainstream? 2.5.4 Exosomes and Micro Vesicles - New Kid on Block 2.6 Cancer Treatment Protocol Under Siege 2.6.1 Issues and Limitations to Liquid Biopsy Adoption - Double Diagnostics 2.6.2 The Cancer Screening Market Opportunity 2.6.2.1 GRAIL - What Is It? 2.6.3 Cancer Management vs. Diagnosis 2.6.3.1 The Role of Risk Assessment 2.6.3.2 Managing Therapy 2.6.3.3 Monitoring Disease - What Is It? 2.6.4 Phases of Adoption - Looking Into The Future 2.6.5 The Promise of Liquid Biopsy 2.7 Structure of Industry Plays a Part 2.7.1 Hospital Testing Share 2.7.2 Economies of Scale 2.7.2.1 Hospital vs. Central Lab 2.7.3 Physician Office Lab's 2.7.4 Physician's and POCT 2.8 Profiles of Key Players 2.8.1 Qiagen 2.8.2 Agena Bioscience 2.8.3 Angle plc 2.8.4 ApoCell 2.8.5 Biocept 2.8.6 BioFluidica 2.8.7 Bio-Rad Laboratories 2.8.8 Boreal Genomics 2.8.10 Chronix Biomedical 2.8.11 Clearbridge BioMedics 2.8.12 Cynvenio 2.8.13 Cytolumina Technologies Corp 2.8.14 CytoTrack 2.8.15 Diagnologix LLC 2.8.16 Epic Sciences 2.8.17 Exosome Diagnostics 2.8.18 Exosome Sciences 2.8.19 Fluidigm Corp 2.8.20 Fluxion Biosciences 2.8.21 Genomic Health 2.8.39 GRAIL 2.8.22 Guardant Health 2.8.23 HansaBiomed 2.8.23 Horizon Discovery 2.8.24 iCellate 2.8.25 Illumina 2.8.26 Inivata 2.8.27 Janssen Diagnostics 2.8.28 Molecular MD 2.8.29 Myriad Genetics 2.8.30 Natera 2.8.31 New Oncology 2.8.32 Personal Genome Diagnostics 2.8.33 RainDance Technologies 2.8.34 Rarecells SAS 2.8.35 Silicon Biosystems 2.8.36 Sysmex Inostics 2.8.37 SRI International 2.8.38 Trovagene 2.8.39 Freenome 3. Market Trends 3.1 Factors Driving Growth 3.1.1 Non Invasive Game Changer 3.1.2 Lower Cost 3.1.3 Greater Accuracy. 3.1.4 Wide Range of Potential Uses 3.1.5 Aging Population 3.2 Factors Limiting Growth 3.2.1 Lower prices 3.2.2 Lack of Standards. 3.2.3 Protocol Resistance. 3.2.4 Initial Adoption Has No Cost Savings 3.3 Instrumentation and Automation 3.3.1 Instruments Key to Market Share 3.3.2 Bioinformatics Plays a Role. 3.4 Diagnostic Technology Development 3.4.1 Next Generation Sequencing Fuels a Revolution 3.4.2 Impact of NGS on pricing 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magneto resistance based assay 4. Liquid Biopsy Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section 4.2 Illumina Forms GRAIL to Enable Early Cancer Detection via Liquid Biopsy 4.3 ASCO: Researchers Present Advances, Ongoing Challenges in Liquid Biopsy 4.4 Guardant Health, SWOG Partner on Prospective NSCLC Liquid Biopsy Study 4.5 Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen 4.6 Biodesix's GeneStrat Liquid Biopsy Lung Cancer Test 4.7 Baylor, TGen Collaborate on Personalized Cancer Treatment Options 4.8 Liquid Biopsy Firm Resolution Bio Gets CLIA Certification for Lab 4.9 Broad Institute Lands $10M Gift to Study Cancer Drug Resistance 4.10 Biocept Q1 Revenues Rise With Test Volume Growth 4.11 CRUK Manchester Institute Joins European Consortium Validating Blood-based Cancer Biomarkers 4.12 New Oncology Closes Financing Round to Promote Genetic Testing from Blood 4.13 Cynvenio to present new clinical data 4.14 EKF, Angle Collaborate for Liquid Biopsy Development 4.15 Trovagene Collaborates with UCSD for EGFR Monitoring in Lung Cancer 4.16 AstraZeneca Initiates CDx Partnerships with Roche, Qiagen 4.17 Horizon, LGC Awarded Research Grant for Cancer Diagnostics 4.18 Merck Serono and Sysmex Inostics Announce Testing Center 4.19 Agena Bioscience Launches Smaller Format MassArray 4.20 Personal Genome Diagnostics Aims for FDA Clearance 4.21 HTG Molecular Diagnostics Files for IPO of up to $60M 4.22 Genomic Health Reports 5 Percent Revenue Growth in Third Quarter 4.23 Biocept, Rosetta Genomics Partner to Profile microRNAs from CTCs 4.24 Inivata Raises $6.6M to Develop ctDNA Assays 4.25 Epic Sciences Raises $30M in Private Financing 4.26 New Release in Line of Liquid Biopsy CLIA Tests 4.27 Collaborators Publish Data on Resolution Bio Liquid Biopsy Test 4.27 Trovagene's Urine-Based Liquid Biopsy Platform Demonstrated in Field 4.28 FDA Sends Pathway Genomics Untitled Letter Over Liquid Biopsy Test 4.29 DNA in blood can track cancer development, response in real time 4.30 Cynvenio Clinical Trial Supports Multi-Template Liquid Biopsy Sequencing 4.31 Startup AccuraGen to Tap China Liquid Biopsy Market With 61-Gene Assay 4.32 Sysmex Corporation and Clearbridge BioMedics to Jointly Develop New Liquid Biopsy System 4.33 MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States 4.34 GATC Biotech's Liquid Biopsy Testing Takes Cost Lead 4.35 Liquid Biotech USA, Inc. Announces Completion of Clinical Study 4.36 Liquid biopsies more effective in some cases than tissue biopsies 4.37 Cancer Genetics, Inc. and ApoCell Announce Partnership for Rare Cell Capture and Detection 4.38 Exosome Diagnostics Launches Liquid Biopsy Test to Rule Out High-Grade Prostate Cancer 4.39 Liquid Biopsy Tests Partially Validated 4.40 FDA Approves Liquid Biopsy 4.41 Liquid Biopsy Predicts Colon Cancer Recurrence 4.42 WaveSense Receives CE-IVD Mark for Cell Enrichment Platform 4.43 For Liquid Biopsy, Size Matters 4.44 Liquid biopsy startup Freenome lands $5.5 million led by Andreessen Horowitz 4.45 Trovagene, USC Collaborate on Deployment of Urine-Based Liquid Biopsy Test 4.46 Circulogene liquid biopsy detects new tumor mass earlier than current imaging methods 4.47 Clinical Utility of Biocept's Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium 4.48 Trovagene to Focus More on Liquid Biopsy Testing Market 4.49 Pancreatic Cancer Gets Prognostic Tool from Liquid Biopsy 4.50 New Start-up to Work on Scalpel-free Liquid Biopsies 4.51 RareCyte announces $30M round 4.52 Liquid Biopsies May Never Replace Tissue Biopsies 4.53 Karius reels in $50M to ramp up infectious disease liquid biopsy 4.54 Liquid Biopsy Passes Test for Nasopharyngeal Cancer 4.55 Exosome Diagnostics Launches the MedOncAlyzer Pan-Cancer Panel 4.56 Lonza Acquires HansaBioMed, Invests in Exosomics 4.57 Controversial Test Highlights Precision Medicine Marketing, Regulatory Issues 4.58 Trovagene Announces Agreement with Global Biopharmaceutical Company 5. Country Market Sizes - North America 6. Country Markets - Europe 7. Country Markets - Asia Pacific 8. Country Markets - Latin America, Africa & The Middle East 9. Global Market Summary 10. Potential Market Opportunity Size For more information about this report visit https://www.researchandmarkets.com/research/53h68b/liquid_biopsy


Patent
Boreal Genomics | Date: 2015-11-02

The invention generally relates to sequencing library preparation methods. In certain embodiments, two template nucleic acids are joined together by a linking molecule, such as a PEG derivative. The linked template nucleic acids is amplified, creating linked amplicons.


Patent
Boreal Genomics | Date: 2014-03-14

The invention includes methods and apparatus for isolating and recovering mutations, especially rare and unknown mutations, without amplifying the sample. In particular, using the disclosed methods, it is possible to separate heteroduplexed nucleic acid strand pair from homoduplexed nucleic acid strand pairs having similar sequences and being at a much higher concentration. Once the heteroduplexed nucleic acids are isolated and recovered, it is straightforward to analyze the sequences of the heteroduplexed nucleic acids, e.g., using sequencing or hybrid assays.


Patent
Boreal Genomics | Date: 2013-09-09

Methods and apparatus providing improved fidelity and specificity when separating nucleic acids from a sample, but without need for amplification. In particular, using the disclosed methods, it is possible to isolate a variant nucleic acid (i.e., a mutation) from a non-target nucleic acid (i.e., a wild-type) when the variant is present in the original sample at a much lower concentration than the non-target, e.g., 1:10,000, without substantial loss of the variant.


The invention generally relates to methods of assessing an individuals risk of developing a disease associated with accumulation of DNA mutations by determining the mutation burden in their circulating cell-free nucleic acid relative to a reference sequence. The invention further relates to establishing a score indicative of the individuals risk by assessing the individuals mutation burden against a mutation burden continuum containing various thresholds associated with different degrees of risk. The reference sequence and the continuum may be constructed from a variety of sources. In certain aspects, methods of the invention relate to compilation of a database of mutation burdens for individuals along with population characteristics for each individual.


Patent
Boreal Genomics | Date: 2015-04-20

Methods and apparatus providing improved fidelity and specificity when separating nucleic acids from a sample, but without need for amplification. In particular, using the disclosed methods, it is possible to isolate a variant nucleic acid (i.e., a mutation) from a non-target nucleic acid (i.e., a wild-type) when the variant is present in the original sample at a much lower concentration than the non-target, e.g., 1:10,000, without substantial loss of the variant.


Patent
Boreal Genomics | Date: 2012-08-23

Methods and apparatus providing improved fidelity and specificity when separating nucleic acids from a sample, but without need for amplification. In particular, using the disclosed methods, it is possible to isolate a variant nucleic acid (i.e., a mutation) from a non-target nucleic acid (i.e., a wild-type) when the variant is present in the original sample at a much lower concentration than the non-target, e.g., 1:10,000, without substantial loss of the variant.

Loading Boreal Genomics collaborators
Loading Boreal Genomics collaborators